As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
Featured article: Emerging roles of C1Q tumor necrosis factor-related proteins in metabolic diseases
Obesity and insulin resistance are key elements of the metabolic syndrome. C1Q Tumor necrosis factor-related proteins (CTRPs) have recently emerged as important regulators of metabolism as a core component in the interrelationship between insulin resistance, adiposity and inflammation.
Pharmacological intervention and lifestyle modification alter expression of CTRPs in circulation and in metabolically active tissues. CTRPs enhance metabolism and possess insulin sensitizing properties; thus, dysregulated expression of CTRPs in metabolic disorders could contribute to the pathogenesis of the disease. For these reasons, CTRPs appear to be promising targets for early detection, prevention and treatment of metabolic disorders.
In this review article, Ramanjaneya and colleagues explore the role of CTRPs in the metbaolic system.
© enotmaks / Fotolia
Why publish with us
- Home for all valid research within pre-clinical and translational medicine
- Gold open access and compatible with growing funder mandates
- Expert Section Editors and an international Editorial Board
- Free access to all content, ensuring a wide dissemination of articles
- High article accesses with more than 55,900 article downloads in 2020
- Companion journal to Journal of Translational Medicine
Aims and scope
Translational Medicine Communications is an interdisciplinary forum for all scientifically valid research from across translational medicine. We publish research that focuses on the biology of disease, as well as preclinical and basic research that is closely associated with medicine. Translational Medicine Communications will also consider reviews, methodology articles, protocols and commentaries.
Our aim is to improve transparency and reproducibility within translational medicine, which is why we consider research papers regardless of outcome or significance of findings, as well as protocols for future research. We aim to serve the translational science community by publishing all scientifically valid and technically sound articles and we are dedicated to facilitating the communication between basic and clinical science.
Translational Medicine Communications is the companion journal to Journal of Translational Medicine.
Journal of Translational Medicine considers articles focusing on information derived from human experimentation to optimise the communication between basic and clinical science.
Editor-in-Chief: Francesco Marincola, Kite Pharma, USA
Dr. Marincola is Global Head of Research at Kite Pharma, Santa Monica, California. He was previously President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation; Chief Research Officer at Sidra Research, Qatar; and Tenured Investigator at the National Institutes of Health, Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine and is the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and the International Society for Translational Medicine. He edited several books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is also an award winning fiction author of The Wise Men of Pizzo and Cat Behind the Window.
Annual Journal Metrics
35 days to first decision for reviewed manuscripts only
29 days to first decision for all manuscripts
62 days from submission to acceptance
20 days from acceptance to publication